PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
4.03
P/E 50-90% of Medical - Pharmaceuticals median of 6.49. Warren Buffett would verify if this discount provides opportunity. Examine competitive position.
0.40
P/S less than half the Medical - Pharmaceuticals median of 7.93. Walter Schloss would verify if this discount reflects fixable issues. Check margins versus peers.
0.93
P/B 50-90% of Medical - Pharmaceuticals median of 1.37. Mohnish Pabrai would examine if this discount presents opportunity.
10.49
P/FCF of 10.49 versus zero FCF in Medical - Pharmaceuticals. Walter Schloss would verify cash flow quality.
6.32
P/OCF near Medical - Pharmaceuticals median of 6.20. Charlie Munger would verify if industry-standard multiples reflect business reality.
0.93
Fair value ratio 50-90% of Medical - Pharmaceuticals median of 1.37. Mohnish Pabrai would examine if this gap presents opportunity.
6.20%
Earnings yield exceeding 1.5x Medical - Pharmaceuticals median of 0.49%. Joel Greenblatt would investigate if high yield reflects hidden value.
9.53%
FCF yield of 9.53% versus zero FCF in Medical - Pharmaceuticals. Walter Schloss would verify cash flow quality.